The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market size is expected to see rapid growth in the next few years. It will grow to $80.1 billion in 2028 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to expanding indications, biomarker research and personalized medicine, clinical trials and research collaborations, global healthcare infrastructure development. Major trends in the forecast period include focus on patient access and affordability, global clinical trial collaborations, immunotherapy combinations, patient-centric approaches, regulatory updates and approvals.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report
Scope Of PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
Market Drivers –
The rising prevalence of cancer cases is expected to propel the growth of the PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market going forward. Cancer is a condition when some cells develop uncontrollably and spread to other body parts. PD-1 and PD-L1 inhibitors help to treat cancer by harnessing the body’s immune system to fight cancer cells. Hence, the rising cancer cases contribute to the growth of the PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market. For instance, in October 2023, according to the European Union Science Hub, a Belgium-based joint research centre of the European Commission, in the two years before to 2022, the number of new cancer cases rose by 2.3%, reaching 2.74 million. Likewise, during the previous two years, there was a 2.4% rise in cancer-related deaths. Therefore, the rise in the prevalence of cancer cases will fuel the growth of the PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market.
Market Trends –
Product innovation has emerged as a key trend gaining popularity in the PD-1 and PDL1 Inhibitors/ immune checkpoint inhibitors market. Major market players are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, In March 2022, Bristol-Myers Squibb, a US-based pharmaceutical company, received FDA approval for Opdualag, which is a fixed-dose combination of nivolumab (Opdivo) and relatlimab, which is a LAG-3 inhibitor. Opdualag is the first LAG-3 inhibitor to receive approval from the US Food and Drug Administration (FDA) to treat patients with metastatic melanoma. The combination of nivolumab and relatlimab in Opdualag aims to enhance the immune response against cancer cells.
The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market covered in this report is segmented –
1) By Product: Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab
2) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online pharmacies
3) By Application: Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Colorectal Cancer, Other Applications
4) By End-Users : Hospitals, Specialty Clinics, Academic and Research Institutions
Get an inside scoop of the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=10788&type=smp
Regional Insights –
North America was the largest region in the PD-1 and PDL1 inhibitors market in 2023. The regions covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Key Companies –
Major companies operating in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Bristol-Myers Squibb Company, Merck and Company, F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., Gilead Sciences Inc., AstraZeneca plc, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc., BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd., Akeso Inc., Alphamab Oncology, Eli Lilly and Company, Boehringer Ingelheim, Xencor Inc., Taiga Biotechnologies Inc., Jiangsu Alphamab Biopharmaceuticals Co. Ltd, Dr. Reddy’s Laboratories Ltd., Laekna Therapeutics, Genentech Inc., Tracon Pharmaceuticals Inc., Celgene, Hangzhou Sumgen Co. Ltd, Agenus Inc., BioNTech SE, Celldex Therapeutics Inc., CytomX Therapeutics Inc.
Table of Contents
1. Executive Summary
2. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Report Structure
3. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Trends And Strategies
4. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market – Macro Economic Scenario
5. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Size And Growth
…..
27. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Read Related Topics:
https://goodprnews.com/organic-snack-food-market-share/
https://goodprnews.com/orthopedic-braces-and-support-devices-and-equipment-market-size/
https://goodprnews.com/poly-vinyl-chloride-market-size/
https://topprnews.com/organic-snack-food-market-trends/
https://topprnews.com/orthopedic-braces-and-support-devices-and-equipment-market-share/
https://topprnews.com/poly-vinyl-chloride-market-share/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
